| 前收市價 | 19.16 |
| 開市 | 19.68 |
| 買盤 | 18.85 x 800 |
| 賣出價 | 22.63 x 800 |
| 今日波幅 | 19.30 - 19.99 |
| 52 週波幅 | 18.85 - 36.30 |
| 成交量 | |
| 平均成交量 | 596,750 |
| 市值 | 5.338B |
| Beta 值 (5 年，每月) | 0.76 |
| 市盈率 (最近 12 個月) | 35.58 |
| 每股盈利 (最近 12 個月) | 0.55 |
| 業績公佈日 | 2024年5月09日 |
| 遠期股息及收益率 | 0.06 (0.32%) |
| 除息日 | 2023年6月07日 |
| 1 年預測目標價 | 29.21 |
ZacksUSNA vs. STVN: Which Stock Should Value Investors Buy Now?
USNA vs. STVN: Which Stock Is the Better Value Option?
Insider MonkeyStevanato Group S.p.A. (NYSE:STVN) Q1 2024 Earnings Call Transcript
Stevanato Group S.p.A. (NYSE:STVN) Q1 2024 Earnings Call Transcript May 11, 2024 Stevanato Group S.p.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Lisa Miles: Good morning, and thanks for joining us. With me today is Franco Stevanato, Executive Chairman; Franco […]
BenzingaItaly Based Stevanato Reports Mixed Q1 Earnings, Revises Annual Guidance On Temporary Destocking
On Thursday, Stevanato Group S.p.A. (NYSE:STVN) reported the first quarter of 236.0 million euros, down 1% Y/Y, compared to the consensus of 237.17 million euros. Adjusted diluted earnings per share were 0.08 euros compared to the consensus of 0.11 euros. Adjusted EBITDA margin for the first quarter was 21.4%. Sales fell due to lower revenue attributable to glass vials in the Biopharmaceutical and Diagnostic Solutions Segment resulting from the ongoing destocking of excess vial inventories that
